NOVEL SYNTHESIS OF PROCESS RELATED IMPURITIES OF VALGANCICLOVIR HYDROCHLORIDE
Objective: The present work aimed at synthesis of process related impurities of valganciclovir by using gancyclovir or monobenzyl ganciclovir as starting material comprising the following steps.
Methods: Selective hydrolysis, reaction with coupling reagent followed by hydrolysis under basic conditions and hydrogenolysis in the presence of catalyst.
Results: The final synthesized compounds 2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)-3-(benzyloxy)propyl acetate 2, 2-((2-amino-6-oxo-1H-purin-9(6H)-yl) methoxy)-3-hydroxy propyl acetate 3, 2-((2-amino-6-oxo-1H-purin-9(6H)-yl) methoxy) propane-1,3-diylbis (2((benzyloxy)carbonyl) amino)-3-methylbutanoate) 6, and 2-((2-amino-6-oxo-1H-purin-9(6H)-yl)methoxy)propane-1,3-diylbis(2-amino-3-methylbutanoate) 7 were sucessfully characterized by using FT-IR, 1H NMR and LC-MS.
Conclusion: The two processes related impurities (monoacetoxy ganciclovir, 3 and bis-valine ester of ganciclovir, 7) of valganciclovir hydrochloride were reported via the formation of key intermediates (acetoxy benzyl ganciclovir, 2 and bis-Cbz-valine ester of ganciclovir, 6)
Keywords: Valganciclovir, Ganciclovir, Antiviral, Acyclic nucleosides
Gorog S. Identification and determination of impurities in drugs. Elsevier; 2000. p. 1-48.
Nageswara Rao R, Nagaraju V. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. J Pharm Biomed Anal 2003;33:335-77.
Gorog S. The importance and the challenges of impurity profiling in modern pharmaceutical analysis. Trends Anal Chem 2006;25:755-7.
Hovorka SW, Schoneich C. Oxidative degradation of pharmaceuticals: Theory, mechanisms and inhibition. J Pharm Sci 2001;90:253-69.
Basak AK, Raw AS, Hakim AH, Furness S, Samaan NI, Gill DS. Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications. Adv Drug Delivery Rev 2007;59:64-72.
Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000;89:781.
Sandor G. Chemical and analytical characterization of related organic impurities in drugs. J Pharma Biomed Anal 2003;377:852-62.
Riley TN. Steric aspects of drug action. Pharmacist 1998;23:40-51.
Roy J, Mohammad G, Banu A. Pharmaceutical analysis and stability of locally manufactured ampicillin trihydrate. Indian Drugs 1993;5:211-8.
Walker GJA, Hogerzeil HV, Hillgreen U. Potency of ergometrine in tropical countries. Lancet 1998;2:393.
Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus. Clin Microbiol Rev 2000;13:83.
Tranos PG, Georgalas I, Founti P, Ladas I. Cytomegalovirus retinitis presenting as vasculitis in a patient with Wegener's granulomatosis. Clin Ophthamol 2008;2:961.
Yust I, Fox Z, Burke M. Retinal and extracular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a Euro SIDA study. Eur J Clin Microbiol Infect Dis 2004;23:550-9.
Curran M, Noble S. Valgancyclovir. Drugs 2001;61:1145.
Martin JC, Tippie MA, McGee DPC, Verheyden JPH. Synthesis and antiviral activity of various esters of 9-[1,3-dihyroxy-2-propoxy methyl] guanine. J Pharm Sci 1987;76:180.
Steininger C. Recent Patent Anti-Infect. Drug Discover 2007;2:53.
Patel K, Trivedi S, Luo S, Zhu X, Pal D, Kern ER. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of gancyclovir. Int J Pharm 2005;305:75-89.
Hongwu G, Ashim KM. NMR spectral data for ester prodrugs of gancyclovir. Magn Reson Chem 2000;38:696-700.
Reddy GM, Raju VVNKVP, Satyanarayana K, Ravindra V, Venkateshwarlu G. Alternative synthesis of Valganciclovir hydrochloride. Synth Commun 2013;43:425-30.
Babu KS, Srinivas P, Madavi YV, Babu I, Reddy GM, Halder P, et al. A succinct synthesis of Valganciclovir hydrochloride, a cytomegalovirus (CMV) retinitis inhibitor. Arkivoc 2011;2:199-208.
Babu KS, Rao MR, Goverdhan G, Srinivas P, Reddy PP, Venkateswarlu, et al. Synthesis of valganciclovir congeners. Synth Commun 2013;43:1751-8.
Schaeffer HJ. Purine derivatives. US patent 4360522, 1982. Chem Abstr 1980;93:186414.
Dvorak CA, Wren DL, Fisher LE, Axt SD, Humphreys ER, Arzeno, HB, et al. US Patent B1; 2002.
Rao DR, Narayanrao KR, Purushottam PV. EP Patent A1; 2007.
Nestor JJ, Womble SW, Maag H. US Patent; 2000.
Katkam S, Rajeshwar RS, Madhusudhan RG, Babu I, Srihari BK, Raghavendar RM, et al. Preparation of valganciclovir and its salts, U. S. Pat. Appl Publ; 2011.
Ramachandra RD, Rajendra KN, Vidyadhar PP. Preparation of valganciclovir, Eur Pat Appl; 2007.
Chandra HK, Yatendra K, Atulya KP, Sushil R, Mukesh KS. Preparation of ganciclovir mono-N-benzyloxycarbonyl-L-valine ester, PCT Int Appl; 2005.
Sharma MK, Raina S, Panda AK, Kumar Y, Khanduri CH. PCT Int Appl A2; 2005.
Arzeno HB. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate. Pat Appl. US5700936 A; 1997.